Validation of longitudinal biomarker screening algorithms for HCC detection in patients with cirrhosis

Amit G Singal1, Qingchun Jin2, Jorge Marrero3

  • 1Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.

Hepatology Communications
|February 23, 2026
PubMed

Insights

Longitudinal GALAD algorithms improve false-positive rates for hepatocellular carcinoma (HCC) detection but significantly decrease sensitivity. Fixed-threshold GALAD shows higher sensitivity but also a higher false-positive rate in HCC surveillance.

Area of Science:

  • Hepatology
  • Biomarker Discovery
  • Cancer Surveillance

Background:

  • Blood-based biomarker panels, including GALAD, are explored as alternatives to ultrasound for hepatocellular carcinoma (HCC) surveillance.
  • Longitudinal evaluation of biomarkers may enhance test performance, but large-scale validation is lacking.

Purpose of the Study:

  • To compare the performance of fixed-threshold GALAD and four longitudinal algorithms (longitudinal GALAD, PALAD, mFB-ALAD, mPEB-ALAD) for HCC surveillance.
  • To validate these algorithms in an external cohort and examine subgroup performance.

Main Methods:

  • Utilized the HCC Early Detection Strategy (HEDS) and Texas HCC Consortium (THCCC) studies.
  • Compared fixed-threshold GALAD (cutoff -1.36) against longitudinal GALAD, PALAD, mFB-ALAD, and mPEB-ALAD algorithms.
  • Assessed sensitivity and false-positive rate (FPR) overall and by age, sex, and cirrhosis etiology.

Main Results:

  • In the THCCC cohort, fixed-threshold GALAD demonstrated higher sensitivity (71.4%) for HCC detection within 6 months of diagnosis compared to longitudinal algorithms (42.9%-55.1%).
  • Fixed-threshold GALAD exhibited a higher FPR (25.4%) than longitudinal GALAD (15.0%) and PALAD (13.0%), but comparable to mPEB-ALAD (22.9%).
  • Longitudinal algorithms showed lower FPRs in subgroups but with reduced HCC sensitivity.

Conclusions:

  • While longitudinal GALAD algorithms improve FPRs compared to fixed-threshold GALAD, this benefit is counteracted by a significant reduction in HCC detection sensitivity.
  • Fixed-threshold GALAD offers higher sensitivity but at the cost of increased false positives, particularly in males and older individuals.
Abstract